Drugs / Solanezumab
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02614131 | Dec 2015 → Dec 2016 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01148498 | Aug 2010 → Aug 2012 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00749216 | Sep 2008 → Jul 2009 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00329082 | May 2006 → May 2008 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT01760005 | Dec 2012 → Apr 2028 expected | familial Alzheimer disease | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04623242 | Dec 2012 → Nov 2019 | familial Alzheimer disease | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT02760602 | Jun 2016 → May 2017 | Alzheimer disease | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT02008357 | Feb 2014 → Dec 2022 | cognitive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01900665 | Jul 2013 → Oct 2016 | Alzheimer disease | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT01127633 | Dec 2010 → Jul 2014 | Alzheimer disease | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT00905372 | May 2009 → Apr 2012 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00904683 | May 2009 → Jun 2012 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Solanezumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00749216 ↗ |
| Known as | LY2062430 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00905372 ↗ |
| Modality | Monoclonal antibody | “LY2062430 (solanezumab) is a humanized anti-A Beta peptide immunoglobulin G-1 (IgG1) monoclonal antibody” NCT00904683 ↗ |
| Route | Intravenous | “100mg QW IV for 12 weeks” NCT00329082 ↗ |
| Target | APP | “Amyloid-beta A4 protein binding agent” CHEMBL1743072 ↗ |